Introduction

Acne vulgaris is a chronic, inflammatory skin disorder that affects most of the population at some point in their lifetime. 

Methods

Acne vulgaris is a chronic, inflammatory skin disorder that affects most of the population at some point in their lifetime. 

Results

Baseline Demographics and Disease Characteristics

- Baseline demographic and disease characteristics were similar across treatment groups (Table 1).
- The majority of subjects were female (60.6%) and white (73.1%) with moderate baseline disease severity (85.0%)

Table 1. Baseline demographics and disease characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>FMX101 4% (n=1378)</th>
<th>Vehicle foam (n=1071)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>16 (16-19)</td>
<td>16 (16-19)</td>
<td>0.86</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>62/706</td>
<td>54/584</td>
<td>0.53</td>
</tr>
<tr>
<td>Race (white/non-white)</td>
<td>1014/364</td>
<td>800/271</td>
<td>0.001</td>
</tr>
<tr>
<td>Baseline IGA</td>
<td>3 (2-4)</td>
<td>3 (2-4)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Efficacy of FMX101 4% in the Pooled Population

- Overall, the majority of subjects were female (60.6%) and white (73.1%) with moderate baseline disease severity (85.0%

Figure 1. Study design

Figure 2. Absolute reduction from baseline in inflammatory lesions for the pooled population

Figure 3. Efficacy of FMX101 4% across baseline disease severities

Figure 4. Reduction in inflammatory lesions for sex subgroups

Figure 5. Reduction in inflammatory lesions for age subgroups

Figure 6. Reduction in inflammatory lesions for race subgroups

Summary

Efficacy of FMX101 4% in the Pooled Population

Overall, the majority of subjects were female (60.6%) and white (73.1%) with moderate baseline disease severity (85.0%

Conclusions

Overall, the majority of subjects were female (60.6%) and white (73.1%) with moderate baseline disease severity (85.0%

Disclosures/Acknowledgment

The authors report the following relevant disclosures:

References


Funding

This study was funded by Foamix Pharmaceuticals Ltd, a wholly owned subsidiary of VYNE Therapeutics Inc.